Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | PPIA | P62937 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708983 | 0.92 | SGMS2 (0.41) | METPPIASGMS2MAPTLMNA | |
| SCHEMBL6710259 | 0.91 | BRD4 (0.36) | METRXFP1MAPTLMNAKDM1A | |
| SCHEMBL6708800 | 0.90 | KDM1A (0.34) | RXFP1MAPTLMNAKDM1A | |
| SCHEMBL6707891 | 0.89 | HSD17B10 (0.33) | RXFP1MAPTLMNAKDM1A | |
| SCHEMBL6710160 | 0.89 | TP53 (0.36) | RXFP1MAPTLMNA | |
| SCHEMBL6713393 | 0.89 | GRIK1 (0.39) | PPIAPTGER1MAPT | |
| SCHEMBL6708956 | 0.89 | LRRK2 (0.38) | MAPTLMNA | |
| SCHEMBL6710036 | 0.88 | KDM1A (0.39) | KDM1A | |
| SCHEMBL6710416 | 0.88 | BRD4 (0.32) | RXFP1MAPTLMNAKDM1A | |
| SCHEMBL6707657 | 0.87 | ALK (0.40) | RXFP1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | MET 3619/4885PPIA 3856/4885RXFP1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.